TNDM Relative Valuation
TNDM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNDM is overvalued; if below, it's undervalued.
Historical Valuation
Tandem Diabetes Care Inc (TNDM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.99 is considered Undervalued compared with the five-year average of -22.22. The fair price of Tandem Diabetes Care Inc (TNDM) is between 286.08 to 376.01 according to relative valuation methord. Compared to the current price of 14.73 USD , Tandem Diabetes Care Inc is Undervalued By 94.85%.
Relative Value
Fair Zone
286.08-376.01
Current Price：14.73
94.85%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
6.75
P/B
Median3y
7.50
Median5y
11.83
-0.37
FCF Yield
Median3y
-0.96
Median5y
-0.26
Competitors Valuation Multiple
The average P/S ratio for TNDM's competitors is 78.56, providing a benchmark for relative valuation. Tandem Diabetes Care Inc Corp (TNDM) exhibits a P/S ratio of 0.99, which is -98.74% above the industry average. Given its robust revenue growth of 22.30%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Tandem Diabetes Care Inc (TNDM) currently overvalued or undervalued?
What is Tandem Diabetes Care Inc (TNDM) fair value?
How does TNDM's valuation metrics compare to the industry average?
What is the current P/B ratio for Tandem Diabetes Care Inc (TNDM) as of Jul 19 2025?
What is the current FCF Yield for Tandem Diabetes Care Inc (TNDM) as of Jul 19 2025?
What is the current Forward P/E ratio for Tandem Diabetes Care Inc (TNDM) as of Jul 19 2025?